On 21 Jan 2020, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) spotted trading -4.59% off 52-week high price. On the other end, the stock has been noted 76.94% away from the low price over the last 52-weeks. The stock changed -0.18% to recent value of $32.91. The stock transacted 104632 shares during most recent day however it has an average volume of 285.19K shares. The company has 36.4M of outstanding shares and 27.76M shares were floated in the market.
Y-mAbs Therapeutics, Inc (YMAB) recently stated financial results for the third quarter of 2019.
“We are very happy with our third quarter results, highlighted by prudent spending combined with notable progress in the preparation of our BLAs for naxitamab and omburtamab, as well commercial ramp-up for the potential launch of both compounds. In addition, we successfully completed a follow-on offering in November, securing gross proceeds of $143.8M, which we believe will – together with our existing cash – be sufficient to cover our operating costs through 2022,” stated Thomas Gad, Founder, Chairman, President and Head of Business Development and Strategy.
Dr. Claus Moller, Chief Executive Officer, continued, “Over the third quarter, we have continued to work hard to make sure that our lead product candidates, naxitamab and omburtamab, advance towards rolling BLA submissions. We still expect the first portion of the rolling BLA for naxitamab to be submitted within the next few weeks, and we expect to file our BLA submission for omburtamab either via a rolling submission to start in 2019 or early 2020 or via a single submission ahead of our predictable completion date at the end of the first quarter of 2020.
Third Quarter 2019 Financial Results
Y-mAbs stated a net loss of $23.9M, or $0.70 per basic and diluted share, for the three months ended September 30, 2019, contrast to a net loss of $11.4M, or $0.42 per basic and diluted share, for the three months ended September 30, 2018.
For the nine months ended September 30, 2019, Y-mAbs stated a net loss of $57.9M, or $1.69 per basic and diluted share, contrast to a net loss of $29.2M, or $1.08 per basic and diluted share, stated for the nine months ended September 30, 2018.
According to the most recent quarter its current ratio was 7.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of 4.64% from the mean of 20 days, 5.88% from mean of 50 days SMA and performed 25.02% from mean of 200 days price. Company’s performance for the week was 6.20%, 6.92% for month and YTD performance remained 5.31%.